πŸ›’ Your Cart

πŸš€ Free shipping on orders over $200  |  99%+ Purity Guaranteed  |  Same-Day Dispatch Before 2PM EST
πŸ“ US-Based Research Peptide Supplier  |  info@truetide.com
🧠 Neurological CAS: 37221-79-7 βœ“ 99%+ Purity

VIP
Vasoactive Intestinal Peptide

β˜…β˜…β˜…β˜…β˜…4.8 / 5  Β·  Neuropeptide with pulmonary and immune data

Select Size

$75
2mg
βœ“
99%+ purity, independently verified by HPLC & mass spectrometry
❄
Lyophilized vials β€” shipped with cold pack, stable at βˆ’20Β°C long term
πŸ“„
Certificate of Analysis included with every order
🚚
Same-day dispatch on orders before 2PM EST
πŸ”’
Discreet, unmarked packaging β€” research-grade handling
⚠️ For Research Use Only. VIP is not approved for human consumption or therapeutic use. This product is sold exclusively as a research chemical for in vitro and laboratory research only.

What is VIP?

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide distributed throughout the central and peripheral nervous systems, GI tract, lungs, and immune tissues. It acts via VPAC1 and VPAC2 receptors to produce vasodilation, smooth muscle relaxation, anti-inflammatory signalling, and neurotransmitter modulation. VIP is studied in models of pulmonary arterial hypertension, neuroinflammation, GI motility, and immune regulation.

CAS 37221-79-7 | MW 3325.9 Da | 28 amino acids

VPAC1/VPAC2 Agonism

Binds VIP receptors VPAC1 (ubiquitous) and VPAC2 (brain, lung, GI) to activate adenylyl cyclase and cAMP/PKA signalling.

Pulmonary Vasodilation

VIP is a potent pulmonary vasodilator. VIP levels are reduced in PAH patients β€” making it a key research compound for pulmonary hypertension models.

Anti-inflammatory

VPAC signalling in macrophages and T-cells shifts immune response toward Th2 and regulatory T-cell phenotypes, reducing pro-inflammatory cytokine production.

Neuroprotection

VIP promotes neuronal survival, neurite outgrowth, and BDNF secretion from astrocytes β€” studied in Alzheimer's and neurodegeneration models.

Pulmonary Arterial Hypertension Trial

Said et al. conducted an inhaled VIP trial in PAH patients, showing significant improvement in 6-minute walk distance, pulmonary vascular resistance, and quality of life over 12 weeks.

Ann Intern Med. 2004;140(6):459–468

Neuroprotection Research

Delgado et al. demonstrated VIP promoted hippocampal neurogenesis and protected against amyloid-Ξ² toxicity in mouse models, supporting its study in neurodegenerative research.

J Neurochem. 2008;107(3):756–769

Inflammatory Bowel Research

Abad et al. showed VIP significantly reduced colitis severity in DSS mouse models by shifting macrophage and T-cell populations toward anti-inflammatory phenotypes.

Gastroenterology. 2003;124(4):961–971

Research Dosing Protocols

PAH clinical trials used 200 Β΅g inhaled 4x/day. Rodent research: 5–50 nmol/kg IV or SC. In vitro immune and neural studies: 0.1–100 nM VIP. Endpoints: pulmonary arterial pressure, cytokine panels (IL-10, TNF-Ξ±, IL-1Ξ²), neural viability assays, and GI motility measurements.

Half-life: VIP has a short plasma half-life (~2 min) due to peptidase cleavage. Delivery method (inhaled, continuous infusion, or peptidase inhibitor co-treatment) is a critical research design variable.
Full NameVasoactive Intestinal Peptide (VIP)
CAS Number37221-79-7
Molecular FormulaC₁₄₇H₂₃₆Nβ‚„β‚„Oβ‚„β‚‚S
Molecular Weight3325.9 Da
Amino Acids28
ReceptorsVPAC1, VPAC2
Purityβ‰₯99% by HPLC
Storageβˆ’20Β°C, desiccated